Skip to content
value.today

Amicus Therapeutics Inc.

Total raised
$295 M
5 rounds on record
Latest round
$30 M
Oct 2023
First round on record
Oct 2010
Today
Private
See the company page

Amicus Therapeutics Inc. is listed today as Amicus Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

5 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Amicus Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2023$30 MNo. 5$10 to $50 million

Amicus Therapeutics Inc.: Raise no. 5, Oct 2023

Investors in this round

2 investors had bought by the notice of Oct 16, 2023: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bradley Campbell · Executive Officer, Director · President and Chief Executive Officer of the Issuer
  • David Clark · Executive Officer · Chief People Officer
  • Ellen S. Rosenberg · Executive Officer · Chief Legal Officer and Corporate Secretary
  • Jeffrey P. Castelli, Ph.D. · Executive Officer · Chief Development Officer
  • Simon Harford · Executive Officer · Chief Financial Officer
  • Burke W Whitman · Director
  • Craig A Wheeler · Director
  • Eiry W Roberts, M.D. · Director
  • Glenn P Sblendorio · Director
  • John F Crowley · Director
  • Lynn D Bleil · Director
  • Margaret G. McGlynn · Director
  • Michael A Kelly · Director
  • Michael G Raab · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Simon Harford, Chief Financial Officer of Issuer. Source: SEC Form D, newest notice filed Oct 16, 2023. Read the notice at the SEC.

equitySEC
Sep 2021$200 MNo. 4$50 to $250 million

Amicus Therapeutics Inc.: Raise no. 4, Sep 2021

Investors in this round

9 investors had bought by the notice of Oct 13, 2021: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$200 M of $200 M offered
Smallest investment taken
$2,149,996
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Over $100 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bradley L. Campbell · Executive Officer, Director · President and Chief Operating Officer of the Issuer
  • Daphne L. Quimi · Executive Officer · Chief Financial Officer of the Issuer
  • David M. Clark · Executive Officer · Chief People Officer of the Issuer
  • Ellen S. Rosenberg · Executive Officer · Chief Legal Officer and Corporate Secretary of the Issuer
  • John F. Crowley · Executive Officer, Director · Chief Executive Officer of Issuer
  • Samantha M. Prout · Executive Officer · Vice President and Global Controller
  • Burke W. Whitman · Director
  • Craig A. Wheeler · Director
  • Eiry L. Roberts · Director
  • Glenn P. Sblendorio · Director
  • Lynn D. Bleil · Director
  • Margaret G. McGlynn · Director
  • Michael A. Kelly · Director
  • Michael G. Raab · Director
  • Robert D. Essner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Daphne Quimi, Chief Financial Officer of the Issuer. Source: SEC Form D, newest notice filed Oct 13, 2021. Read the notice at the SEC.

equity, optionsSEC
Jul 2016$5 MIssued in a merger or acquisition$2 to $10 million

Amicus Therapeutics Inc.: Private sale, Jul 2016

Investors in this round

18 investors had bought by the notice of Jul 19, 2016: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$5,000
Finders' fees
$5,000
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Daphne D. Quimi · Executive Officer
  • John Crowley · Executive Officer, Director
  • William D. Baird, III · Executive Officer
  • Craig A. Wheeler · Director
  • Donald J. Hayden, Jr. · Director
  • Glen G. Sblendorio · Director
  • Margaret G. McGlynn · Director
  • Michael G. Raab · Director
  • Robert D. Essner · Director
  • Sol D. Barer · Director
  • Ted W. Love · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ellen S. Rosenberg, General Counsel and Corporate Secretary. Source: SEC Form D, newest notice filed Jul 19, 2016. Read the notice at the SEC.

equitySEC
Nov 2013$15 MNo. 3$10 to $50 million

Amicus Therapeutics Inc.: Raise no. 3, Nov 2013

Investors in this round

5 investors had bought by the notice of Dec 3, 2013: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bradley L. Campbell · Executive Officer
  • Daphne W. Quimi · Executive Officer
  • David J. Lockhart · Executive Officer
  • Enrique R. Dilone · Executive Officer
  • Jayne W. Gerskowitz · Executive Officer
  • Jeffrey P. Castelli · Executive Officer
  • Joan C. Winterbottom · Executive Officer
  • John F. Crowley · Executive Officer, Director
  • John R. Kirk · Executive Officer
  • Ken R. Valenzano · Executive Officer
  • Kenneth W. Peist · Executive Officer
  • William D. Baird, III · Executive Officer
  • Donald J. Hayden, Jr. · Director
  • Glenn G. Sblendorio · Director
  • James J. Barrett · Director
  • James N. Topper · Director
  • Margaret G. McGlynn · Director
  • Michael G. Raab · Director
  • Robert W. Essner · Director
  • Sol J. Barer · Director
  • Ted W. Love · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William D. Baird III, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 3, 2013. Read the notice at the SEC.

equity, optionsSEC
Nov 2013$15 MIssued in a merger or acquisition$10 to $50 million

Amicus Therapeutics Inc.: Private sale, Nov 2013

Investors in this round

29 investors had bought by the notice of Dec 3, 2013: 29 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bradley L. Campbell · Executive Officer
  • Daphne W. Quimi · Executive Officer
  • David J. Lockhart · Executive Officer
  • Enrique R. Dilone · Executive Officer
  • Jayne W. Gerskowitz · Executive Officer
  • Jeffrey W. Castelli · Executive Officer
  • Joan C. Winterbottom · Executive Officer
  • John F. Crowley · Executive Officer, Director
  • John R. Kirk · Executive Officer
  • Ken R. Valenzano · Executive Officer
  • Kenneth W. Peist · Executive Officer
  • William D. Baird, III · Executive Officer
  • Donald J. Hayden, Jr. · Director
  • Glenn G. Sblendorio · Director
  • James J. Barrett · Director
  • James N. Topper · Director
  • Margaret G. McGlynn · Director
  • Michael G. Raab · Director
  • Robert W. Essner · Director
  • Sol J. Barer · Director
  • Ted W. Love · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William D. Baird, III, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 3, 2013. Read the notice at the SEC.

equitySEC
Jul 2012$19 MNo. 2$10 to $50 million

Amicus Therapeutics Inc.: Raise no. 2, Jul 2012

Investors in this round

1 investor had bought by the notice of Jul 30, 2012: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$19 M of $19 M offered
Smallest investment taken
$18,582,360
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$5 million to $25 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bradley L. Campbell · Executive Officer
  • Daphne W. Quimi · Executive Officer
  • David J. Lockhart · Executive Officer
  • Enrique R. Dilone · Executive Officer
  • John F. Crowley · Executive Officer, Director
  • John R. Kirk · Executive Officer
  • Ken R. Valenzano · Executive Officer
  • Kenneth W. Peist · Executive Officer
  • Pol F. Boudes · Executive Officer
  • Robert W. Winkler · Executive Officer
  • William D. Baird, III · Executive Officer
  • Donald J. Hayden, Jr. · Director
  • Glenn G. Sblendorio · Director
  • James J. Barrett · Director
  • James N. Topper · Director
  • Margaret G. McGlynn · Director
  • Michael G. Raab · Director
  • Robert W. Essner · Director
  • Sol J. Barer · Director
  • Ted W. Love · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “A sale of unregistered shares was made to one accredited investor.”

Signed by John F. Crowley, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 30, 2012. Read the notice at the SEC.

equitySEC
Oct 2010$31 MNo. 1$10 to $50 million

Amicus Therapeutics Inc.: Raise no. 1, Oct 2010

Investors in this round

1 investor had bought by the notice of Nov 5, 2010: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$31 M of $31 M offered
Smallest investment taken
$31,284,583
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$25 million to $100 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bradley L Campbell · Executive Officer
  • David R Lockhart · Executive Officer
  • Geoffrey P Gilmore · Executive Officer
  • John F Crowley · Executive Officer, Director · Chairman and Chief Executive Officer
  • John R Kirk · Executive Officer
  • Ken R Valenzano · Executive Officer
  • Matthew R Patterson · Executive Officer
  • Pol F Boudes · Executive Officer
  • S Nicole Schaeffer · Executive Officer
  • Alexander E Barkas · Director
  • Donald J Hayden · Director
  • Glenn P Sblendorio · Director
  • James N Topper · Director
  • James R Barrett · Director
  • Margaret G McGlynn · Director
  • Michael G Raab · Director
  • P Sherrill Neff · Director
  • Sol J Barer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “A sale of unregistered shares was made to one accredited investor.”

Signed by Geoffrey P. Gilmore, General Counsel and Secretary. Source: SEC Form D, newest notice filed Nov 5, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Amicus Therapeutics, Inc., its revenue in fiscal 2025 came from these product and service lines: Galafold $521.70 million (82%), Pombiliti + Opfolda $112.51 million (18%).

    Annual report (SEC XBRL) · Dec 2025

  • Amicus Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2023).

    SEC Form D · Oct 2023

  • Revenue range over time, as stated in its notices: revenue between $25 million and $100 million in 2010; revenue between $5 million and $25 million in 2012; revenue between $1 million and $5 million in 2013; revenue of over $100 million in 2021.

    SEC Form D (revenue range) · Oct 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2023

Products#

  • biopharmaceutical

From the company page of Amicus Therapeutics, Inc..

Services#

No services of Amicus Therapeutics Inc. are on record.

Investors#

No investor of Amicus Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 9 investors.

Largest shareholders today

Institutions holding Amicus Therapeutics, Inc. shares, as of Jun 30, 2026.

Source: SEC Form 13F holdings reports · as of Jun 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Amicus Therapeutics Inc.
NameRoleNamed in
Bradley CampbellPresident and Chief Executive Officer of the IssuerOct 2023
David ClarkChief People OfficerOct 2023
Ellen S. RosenbergChief Legal Officer and Corporate SecretaryOct 2023
Jeffrey P. Castelli, Ph.D.Chief Development OfficerOct 2023
Simon HarfordChief Financial OfficerOct 2023
Bradley L. CampbellPresident and Chief Operating Officer of the IssuerOct 2021
Daphne L. QuimiChief Financial Officer of the IssuerOct 2021
David M. ClarkChief People Officer of the IssuerOct 2021
John F. CrowleyChief Executive Officer of IssuerOct 2021
Samantha M. ProutVice President and Global ControllerOct 2021
Daphne D. QuimiExecutive officerJul 2016
John CrowleyExecutive officerJul 2016
William D. Baird, IIIExecutive officerJul 2016
Daphne W. QuimiExecutive officerDec 2013
David J. LockhartExecutive officerDec 2013
Enrique R. DiloneExecutive officerDec 2013
Jayne W. GerskowitzExecutive officerDec 2013
Jeffrey P. CastelliExecutive officerDec 2013
Jeffrey W. CastelliExecutive officerDec 2013
Joan C. WinterbottomExecutive officerDec 2013
John R. KirkExecutive officerDec 2013
Ken R. ValenzanoExecutive officerDec 2013
Kenneth W. PeistExecutive officerDec 2013
Pol F. BoudesExecutive officerJul 2012
Robert W. WinklerExecutive officerJul 2012
Bradley L CampbellExecutive officerNov 2010
David R LockhartExecutive officerNov 2010
Geoffrey P GilmoreExecutive officerNov 2010
John F CrowleyChairman and Chief Executive OfficerNov 2010
John R KirkExecutive officerNov 2010
Ken R ValenzanoExecutive officerNov 2010
Matthew R PattersonExecutive officerNov 2010
Pol F BoudesExecutive officerNov 2010
S Nicole SchaefferExecutive officerNov 2010
Bradley CampbellPresident and Chief Executive Officer of the IssuerOct 2023
Burke W WhitmanDirectorOct 2023
Craig A WheelerDirectorOct 2023
Eiry W Roberts, M.D.DirectorOct 2023
Glenn P SblendorioDirectorOct 2023
John F CrowleyDirectorOct 2023

About

Company in Cranbury, United States.